In conclusion, avitinib alleviates bleomycin-induced pulmonary fibrosis and inhibits lung fibroblast activation, migration and ECM accumulation by inhibiting TGF-β1/Smad3 signalling. The gene discussed is TGFB1; the disease is pulmonary fibrosis.